. 2019 Aug 7;8(2):78–131. doi: 10.12997/jla.2019.8.2.78

Table 10. Drug selection according to dyslipidemia treatment standard (primary goal: LDL-C, secondary goal: non-HDL-C).

Dyslipidemia classification	Order	Type of drug	Method of administration	Strength of recommendation	Level of evidence
Hypercholesterolemia	Basic drugs	Statin	Adjust dose according to CVD risk to meet target LDL-C (when meeting target is difficult for high-risk and very high-risk groups, adjust dose to lower LDL-C by >50% of the baseline)	I	A
	Other drugs	Bile acid sequestrant, ezetimibe		IIa	B
	Combination therapy	Statin+ezetimibe		IIa	B
		Statin+bile acid sequestrant		IIb	C
		Statin (±ezetimibe)+PCSK9 inhibitor	Statin (±ezetimibe) for very high-risk group when target LDL-C is not met even with statin monotherapy or statin/ezetimibe therapy	IIb	A
Hypercholesterolemia+hypertriglyceridemia	Monotherapy	Statin		I	A
	Combination therapy	Statin+fibrate		IIa	A
		Statin+gemfibrozil		III	B
		Statin+omega-3 fatty acid		IIa	C
Hypertriglyceridemia	Basic drugs	Fibrate		I	B
Hypertriglyceridemia	Basic drugs	Omega-3 fatty acid		IIa	B
When drug therapy is considered for hypo-HDL cholesterolemia	Basic drugs	Statin, fibrate		IIb	B

LDL-C, low density lipoprotein cholesterol; HDL-C, high density lipoprotein cholesterol; CVD, cardiovascular disease; PCSK9, proprotein convertase subtilisin/kexin type 9.